The EU’s Innovative Medicines Initiative (IMI) public-private partnership (PPP) – now in its second phase – has demonstrated how it can deliver medical solutions to complex disease issues.
At a Stakeholder Forum in Brussels in June, Rudolf Strohmeier, Deputy Director General of the European Commission's research and innovation directorate-general, said the aim of the forum, the first since the launch of IMI’s second phase last year, was to assess how far the initiative has come and what new opportunities might be available to different member groups. The IMI is a joint undertaking between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The first phase began in 2008 and it is Europe’s largest PPP, with a €3.3bn budget for the period 2014–2024.
This is a chance to take stock of what we have achieved and to look to the future
‘This is a chance to take stock of what we have achieved and to look to the future. The health sector faces many challenges, including tightening national health budgets and I am convinced that the only way forward is more research innovation,’ said Strohemeier, who is also Deputy Chair of IMI. The IMI had, he told a 500-strong audience, brought ‘new insight’ and sought to cultivate ‘new breakthroughs’ in medical research.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.